Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 5/20 | 0.50 |
| ▸ | KIT | P10721 | 2/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | MIF | P14174 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 3/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29615472 | 1.00 | PKM (0.50) | PKMKITDYRK1AMIFFLT3 | |
| SCHEMBL34464684 | 0.82 | PKM (0.57) | PKMKITDYRK1AMIFFLT3 | |
| SCHEMBL22919154 | 0.82 | PKM (0.57) | PKMKITDYRK1AMIFFLT3 | |
| SCHEMBL22918691 | 0.79 | FLT3 (0.41) | PKMKITFLT3PIK3CA | |
| SCHEMBL29614089 | 0.79 | FLT3 (0.41) | PKMKITFLT3PIK3CA | |
| SCHEMBL22918757 | 0.76 | KIT (0.56) | KITFLT3 | |
| SCHEMBL376287 | 0.76 | PKM (0.54) | PKMDYRK1AMIFFLT3CDK2 | |
| SCHEMBL1992877 | 0.75 | FLT3 (0.50) | PKMKITDYRK1AMIFFLT3 | |
| SCHEMBL28862348 | 0.75 | DYRK1A (0.57) | PKMKITDYRK1AMIFFLT3 | |
| SCHEMBL29613692 | 0.75 | DYRK1A (0.57) | PKMKITDYRK1AMIFFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109697-A1 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2026-04-23 | — | — | US | disclosed |
| US-20220267320-A1 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2022-08-25 | — | — | US | disclosed |
| CN-114174293-A | 4- (imidazo [1,2-a ] pyridin-3-yl) -pyrimidine derivatives | 默克专利股份公司 | 2022-03-11 | — | — | CN | disclosed |
| US-8124764-B2 | Fused heterocyclyc inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2303881-A2 | FUSED HETEROCYCLYC INHIBITORS OF HISTONE DEACETYLASE AND/OR CYCLIN-DEPENDENT KINASES | GILEAD SCIENCES, INC. (US) | 2011-04-06 | — | — | EP | disclosed |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2010009155-A2 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109697-A1 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES | CHUK, CNKSR1, KIT | PKM 2432/4885KIT 3/4885DYRK1A 1301/4885 |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC7 | PKM 692/4885KIT 648/4885DYRK1A 3146/4885 |
| US-20220267320-A1 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES | NCOA3, NCOR1, NCOA4 | PKM 3643/4885KIT 273/4885DYRK1A 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.